lixisenatide: Clinical Trials

64 trials of lixisenatide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

52 completed, 5 terminated, 3 unknown, 2 recruiting. 32 Phase 3, 15 Phase 4, 7 Phase 1, 7 Phase 2, 3 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 332Completed 31, Terminated 1
Phase 415Completed 9, Recruiting 2, Unknown 2, Enrolling by invitation 1, Terminated 1
Phase 17Completed 5, Terminated 1, Unknown 1
Phase 27Completed 5, Terminated 1, Unknown 1
Not applicable3Completed 2, Terminated 1

Follow lixisenatide: new trials by email Literature Review of lixisenatide trials Research Report on lixisenatide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
iGlarLixi (insulin glargine/lixisenatide), standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs) - Type 2 Diabetes
Phase 4RecruitingShanghai Zhongshan Hospital13162025-12-132026-07-07
Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
lixisenatide + glargine, Intensive insulin therapy - Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia
Phase 4Enrolling by invitationMedical University of Warsaw1002025-07-102025-09-19
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
iGlarLixi (insulin glargine/lixisenatide) - Type 2 Diabetes
Phase 4CompletedSanofi1052025-01-062026-07-10
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine) - Type 2 Diabetes (T2D)
Phase 4RecruitingSanofi6782024-12-102026-03-17
The Effect of Lixisenatide on the Effect of Pituitary Hormones
Placebo, Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector - Healthy, Type 1 Diabetes
Phase 4UnknownUniversity of Tartu102023-04-172023-06-12
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
Insulin glargine/Lixisenatide, IDegAsp, Metformin - Type 2 Diabetes Mellitus
Phase 3CompletedSanofi5822022-07-072025-09-24
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Insulin glargine/Lixisenatide - Type 2 Diabetes Mellitus
Phase 4CompletedSanofi1242022-01-272025-09-09
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA - Cardiovascular Events, Type2 Diabetes
Active not recruitingBrigham and Women's Hospital7814302021-08-012026-08-13
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin - Type 2 Diabetes Mellitus
Phase 3CompletedSanofi4262019-02-192022-07-19
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Lixisenatide (AVE0010) - Type 2 Diabetes Mellitus
Phase 3CompletedSanofi8782019-02-152022-07-19
The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
Basal insulin glargine and lixisenatide, Basal insulin Basaglar/Lantus + gliclazide MR, Metformin - Diabetes Mellitus, Type 2
Phase 4CompletedLMC Diabetes & Endocrinology Ltd.1192018-10-022021-02-25
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010), INSULIN GLARGINE (HOE901), Metformin - Type 2 Diabetes Mellitus
Phase 3CompletedSanofi2472018-06-192022-04-25
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
Lixisenatide, placebo - Parkinson Disease
Phase 2CompletedUniversity Hospital, Toulouse1562018-06-132025-11-28
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy - Type 2 Diabetes Mellitus
Phase 3TerminatedSanofi2412018-02-202022-03-28
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
iGlarLixi, Insulin Glargine, Metformin - Type 2 Diabetes Mellitus
Phase 3CompletedPopulation Health Research Institute1612017-06-272020-11-13
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
Lixisenatide (AVE0010), Placebo, Basal Insulin - Type 2 Diabetes Mellitus
Phase 1CompletedSanofi232017-05-172022-04-25
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
Lixisenatide (AVE0010), Sulfonylurea, metformin - Diabetes Mellitus, Type 2
Phase 4CompletedSanofi1842017-02-232022-04-25
Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
Lixisenatide, Basal insulins - Diabetes Mellitus Type 2
Phase 4TerminatedLaniado Hospital22016-07-122017-04-07
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide - Type 2 Diabetes Mellitus
Phase 3CompletedSanofi5142016-07-062022-03-25
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Oral anti-diabetic drugs - Type 2 Diabetes Mellitus
Phase 3CompletedSanofi5212016-05-232020-06-16

Showing 20 of 64. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (53)  ·  Diabetes Mellitus (8)  ·  Hyperglycemia (8)  ·  Insulin Resistance (3)  ·  Diabetes Mellitus, Type 1 (2)  ·  Acute Coronary Syndrome (1)  ·  Diabetic Nephropathies (1)  ·  Gastroparesis (1)  ·  Hypoglycemia (1)  ·  Kidney Diseases (1)  ·  Motor Activity (1)  ·  Parkinson Disease (1)

Sponsors

Sanofi (45)  ·  Amsterdam UMC, location VUmc (1)  ·  Brigham and Women's Hospital (1)  ·  Erasme University Hospital (1)  ·  Hospital Universitari Vall d'Hebron Research Institute (1)  ·  LMC Diabetes & Endocrinology Ltd. (1)  ·  Laniado Hospital (1)  ·  Lund University (1)  ·  Medical University of Vienna (1)  ·  Medical University of Warsaw (1)  ·  Novo Nordisk A/S (1)  ·  Population Health Research Institute (1)  ·  Profil Institut für Stoffwechselforschung GmbH (1)  ·  Royal Adelaide Hospital (1)  ·  Seoul National University Hospital (1)

Countries

United States (23)  ·  Germany (21)  ·  Canada (15)  ·  Romania (15)  ·  Mexico (14)  ·  Poland (14)  ·  Russia (14)  ·  Japan (12)  ·  Spain (11)  ·  Ukraine (11)  ·  Chile (10)  ·  France (10)  ·  India (10)  ·  Czechia (9)  ·  Italy (9)

Top investigators

David Russell-Jones, MBBS PhD (1)  ·  Elisabetta Patorno, MD, DrPH (1)  ·  Fariba Shojaee-Moradie, BSc, PhD (1)  ·  Filip K Knop, Assoc. Prof. (1)  ·  Hertzel Gerstein, MD (1)  ·  Juris Meier, MD (1)  ·  Karen L Jones, PhD (1)  ·  Leszek Czupryniak, Prof. Dr. hab.n.med. (1)  ·  Margot Umpleby, BA, PhD (1)

Results publications

PMID 39963952, PMID 29974618, PMID 31956422, PMID 36809495, PMID 23628617, PMID 25130920, PMID 27252787, PMID 27267268, PMID 27319011, PMID 29923298, PMID 30550345, PMID 31114694, PMID 31848983, PMID 36999231, PMID 17098089, PMID 17622601, PMID 20722676, PMID 22432104, PMID 22564709, PMID 23368510, PMID 23524641, PMID 23536584, PMID 23537041, PMID 23564915, PMID 23627775, PMID 23645885, PMID 23698396, PMID 24117597, PMID 24236828, PMID 24639432, PMID 24650952, PMID 25012990, PMID 25887358, PMID 26039935, PMID 26342556, PMID 26537183, PMID 26630143, PMID 27222510, PMID 27284114, PMID 27311491, PMID 27527848, PMID 27650977, PMID 28124820, PMID 28188240, PMID 28345162, PMID 28357772, PMID 28386990, PMID 28432746, PMID 28449402, PMID 28554908

NIH funding

2009 (2), 2008 (1), 2014 (1)